All news

Cash isn't expected to last a year as losses widen at Revelation Biosciences (REVB).

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

Revelation Biosciences (REVB) reported a widening net loss of $9.65 million for the nine months ended September 30, 2026, compared to $6.40 million in the same period last year. The company's cash and cash equivalents of $9.12 million are not expected to sustain operations for another year, raising substantial doubt about its ability to continue as a going concern.

Read original source

REVB company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.